Novartis Ushers in a New Era with FDA Approval of Rhapsido (Remibrutinib) for Chronic Spontaneous Urticaria

On September 30, Novartis announced that the U.S. Food and Drug Administration’s approval of Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU). This innovative therapy is the first oral, targeted BTK inhibitor designed exclusively for CSU- a condition marked by unpredictable outbreaks of hives and severe itching, adversely affecting millions.

CSU is notoriously difficult to manage. Many patients fail to find relief with traditional antihistamines, and injectable biologics remain underused due to cost, accessibility, and administration hurdles. Rhapsido promises a paradigm shift: taken orally twice daily, it specifically blocks Bruton’s tyrosine kinase (BTK), a protein crucial in triggering histamine and proinflammatory mediator release.

Clinical studies cited by Novartis show that patients experienced rapid and sustained symptom improvement, with a third reporting complete resolution of symptoms in twelve weeks.

Experts in allergy and dermatology stated that remibrutinib as a major advance, noting its potential for patients who have exhausted other therapies or want to avoid injectables. Moreover, Rhapsido removes the need for frequent lab monitoring, simplifying the treatment journey. Novartis is submitting regulatory filings globally, and broader clinical development is underway for other immunologic diseases.

The company’s patient support programs and educational efforts are launching alongside the approval. Advocacy groups are optimistic that the therapy will bridge gaps in access and empower patients living with this chronic disease.